Allan Jordan

Views & Analysis

We speak to R&D experts to find out how oncology biotechs can get the support they need to be successful in the competitive UK ecosystem

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.